01.08.2022 • NewsDow

Dow and Al-Hejailan in Saudi MDEA Venture

Dow and Saudi family business Al-Hejailan Group have signed a Memorandum of Understanding to form a joint venture to design, build and operate a methyl diethanolamine (MDEA) plant in PlasChem Park in Jubail.

“Saudi Arabia is a significant player in both the regional and global petrochemicals market, with further growth expected in the coming years,” said Faisal Al-Hejailan, CEO of the Al-Hejailan Group, noting that the agreement with Dow aligns with the Saudi group's strategy of participating in the downstream industry.

Dow will hold 25% of the JV, while Al-Hejailan will hold 75%. Construction of the plant, which will use Dow’s technology, is expected to start in 2024 with operations scheduled to begin in 2025. Al-Hejailan will build and operate the facility, while Dow will be responsible for marketing the MDEA.

In addition, Dow will build its own downstream manufacturing facility, taking MDEA from the venture to produce its Ucarsol and Accutrace products. Ucarsol is a gas-treating solvent that is specifically designed to remove CO2 and hydrogen sulfide in natural and synthesis gas processing. Accutrace is a molecular fuel marking technology.

Dow said this investment will position it to further enable local solutions for the energy transition. The facility is expected to come on stream in late 2024.

Author: Elaine Burridge, Freelance Journalist

© AVAVA/Shutterstock
© AVAVA/Shutterstock

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.